Immunomedics' drug Trodelvy was granted accelerated approval by the U.S. Food and Drug Administration in April for the treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease.
from Gilead Sciences buying Immunomedics in $21 billion deal
https://ift.tt/32roPME
https://ift.tt/eA8V8J
No comments:
Post a Comment